FILANA THERAPEUTICS, INC. (FLNA) Earnings Signals & AI Vibe Check

Latest Filing: 10-K  |  Filed Dec 03, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for FILANA THERAPEUTICS, INC.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, FILANA THERAPEUTICS, INC.'s filing signal turned negative.
earningsVibe SuperAnalyst™ Verdict: TURNED NEGATIVE

Signal Performance — Stock Price Since Filing

30-Day Change
-15.90%
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Continuing Negative
GEMINI
Turned Negative
CLAUDE
Turned Negative
CHATGPT
Continuing Negative

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does FILANA THERAPEUTICS, INC. actually do?
Answer:
Filana Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing transformative medicines for central nervous system (CNS) disorders, particularly Tuberous Sclerosis Complex (TSC)-related epilepsy. The company's science centers on modulating the activity of the filamin A protein, a novel target for TSC-related epilepsy. Its lead drug candidate, simufilam, was previously evaluated for Alzheimer's disease, a program that was discontinued in mid-2025. Filana Therapeutics holds worldwide rights to its drug development programs, supported by a portfolio of patents and a license agreement with Yale University for simufilam. The company is currently navigating a clinical hold from the FDA for its planned proof-of-concept trial in TSC-related epilepsy.
Question:
What are FILANA THERAPEUTICS, INC.'s revenue drivers?
Answer:
The company has not generated any product revenue and expects to continue incurring losses for the foreseeable future as it advances its product candidates through development and clinical trials.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required